GLP1R and thyroid gland carcinoma: During follow-up, 76 patients with incident thyroid cancer were identified in the GLP1 receptor agonist group and 184 in the DPP4 inhibitor group; the incidence rates were 1.33 and 1.46 per 10 000 person years, respectively.